Physician profile
Thomas Yu
NPI 1619963162
$14,349.07
in general payments reported to CMS, 2019-2025
42 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $656 · 2021: $4,300 · 2022: $3,039 · 2023: $2,060 · 2024: $1,871 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.03 |
| Education | $315.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,899.96 | 2019-2022 | |
| Abbvie INC. | $1,291.85 | 2019-2025 | Rinvoq, Botox |
| Janssen Biotech, INC. | $897.16 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $750.11 | 2019-2025 | Aklief, Oracea, Twyneo |
| Lilly USA, LLC | $582.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $554.00 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $443.66 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $433.94 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $421.94 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $407.91 | 2019-2025 | |
| Pfizer INC. | $394.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $382.37 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $322.24 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $317.06 | 2020-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $300.08 | 2023-2025 | Zoryve |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $267.66 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $245.12 | 2020-2025 | Jublia, Arazlo, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.42 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $177.90 | 2022-2024 | Vtama |
| Almirall LLC | $158.58 | 2019-2023 | Klisyri |
| Organon LLC | $98.69 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.38 | 2022-2023 | Sotyktu |
| Dermira, INC. | $78.38 | 2019-2021 | |
| Journey Medical Corporation | $65.84 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $57.97 | 2020-2021 | |
| Revance Therapeutics, INC. | $57.91 | 2025 | Daxxify |
| Biowound Solutions, INC. | $53.17 | 2025 | Bio-Connekt |
| Epi Health, LLC | $49.36 | 2020-2022 | |
| Biofrontera INC. | $47.50 | 2021 | |
| Hill Dermaceuticals, INC. | $37.39 | 2023 | Tolak |
| Botanix Sb INC | $35.02 | 2025 | Sofdra |
| Blueprint Medicines Corporation | $32.82 | 2023 | |
| Mission Pharmacal Company | $31.53 | 2019 | |
| Encore Dermatology INC. | $25.81 | 2020 | |
| Springworks Therapeutics, INC. | $24.66 | 2025 | Gomekli |
| Cook Medical LLC | $22.96 | 2019 | |
| Organogenesis INC. | $19.89 | 2021 | |
| Kerecis Limited | $19.01 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Sandoz INC. | $17.07 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Kyowa Kirin, INC. | $13.02 | 2021 | |
| Prugen, INC. Pharmaceuticals | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.